THERANEXUS: 2020 FULL-YEAR RESULTS AND UPDATE ON THE PROGRESS OF MAIN PROGRAMS
Lyon, 7 April 2021 - Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its results for the year ending 31 December 2020 and presents an update on the progress of its main programs.
Franck Mouthon, Chairman, CEO and co-founder of Theranexus, made the following comments: 2020 - a year of health crisis - was marked by rigorous expenditure management and cost control. Our cash flow, underpinned by the new equity line implemented in early 2021, is in a good position and will notably ensure our capacity to continue development of the BBDF-101 program. Moreover, we are actively pursuing our partnership discussions for THN102 and restate our confidence in reaching an agreement by the end of the first half of 2021.